

Grifols signs an agreement with ImmunoTek to open 21 plasma centers and further advances on its expansion plan

- Grifols reaffirms its commitment to expanding its plasma supply to meet the growing demand for plasma therapies
- Grifols will develop 21 additional plasma collection centers through a collaboration with ImmunoTek
- Once all centers become operative and ramped-up, collectively they will supply an additional plasma capacity of 1 million liters annually
- 5 centers are currently in operation. It is foreseen that all the 21 centers will be established and operating by October 2022
- Grifols has committed to fund these operations

Barcelona, July 30, 2021.- Grifols (MCE: GRF, MCE: GRF.P y NASDAQ: GRFS), a global leader in the production of plasma-derived medicines with more than 100 years of history dedicated to enhancing people's health and well-being, closed a collaboration agreement with the U.S. firm ImmunoTek Bio Centers LLC, specialized in the opening and construction of plasma centers via strategic accords and contracts with healthcare companies. Through this accord, Grifols will accelerate the execution of its expansion plan and bolster its integrated network of plasma centers.

Grifols and ImmunoTek will combine their expertise for the development, construction and operation of 21 plasma collection centers with a capacity of 1 million liters of plasma per year.

Out of the total 21 centers in the agreement, 5 are already operating and are currently in the ramp-up phase. All 21 plasma collection centers will be established and functioning by October 2022. Grifols will have access to the plasma from the 5 centers in operation.

For Eduardo Herrero, President of Grifols Bioscience Industrial Group, "Plasma is one of the central pillars of Grifols' long-term, sustainable growth strategy. This agreement allows us to free up internal operating resources and focus on promoting, optimizing and expanding the capacity of our current plasma-center network, while working to open new centers with an exceptional partner like ImmunoTek."

GRIFOLS

ImmunoTek CEO Jerome Parnell III said, “This partnership continues ImmunoTek’s aggressive expansion, and we are very pleased to have a leader like Grifols as a close partner.”

Grifols remains committed to further expanding its plasma availability to meet anticipated robust demand and guarantee the supply of essential plasma therapies for patients who need them.

About the agreement with ImmunoTek

Under the agreement, ImmunoTek will manage the centers in accordance with a business plan previously arranged with Grifols. All centers are expected to be licensed by the U.S. Food and Drug Administration (FDA) and European health authorities.

The centers will exclusively serve Grifols manufacturing needs.

Grifols has committed to fund the opening and development of the centers.

Grifols retained the legal services of Osborne Clarke S.L.P. and Proskauer Rose L.L.P. for this transaction.

Acquisition of 32 plasma centers in the United States in 1H 2021 provides access to 1.4 million additional liters of plasma per year

Prior to this agreement, Grifols closed the acquisition of 32 plasma centers in the United States in the first semester of 2021, another step forward toward consolidating the leadership of its global network. Specifically, Grifols acquired 25 centers from BPL Plasma Inc. in March 2021 and seven plasma centers from Kedrion in April 2021.

These centers will provide an additional capacity of roughly 1.4 million liters of plasma per year, which the company can immediately access.

Additionally Grifols also plans on opening 15 to 20 new plasma centers in the second half of 2021.

Investor contact:

Investor Relations and Sustainability

inversores@grifols.com - investors@grifols.com

Tel. +34 93 571 02 21

Media contacts:

<p>Raquel Lumbreras Raquel_lumbreras@duomocomunicacion.com Borja Gómez Borja_gomez@duomocomunicacion.com Duomo Comunicación – Grifols Press Office Tel. +34 91 311 92 89 - 91 311 92 90 +34 659 57 21 85 / +34 650 40 22 25</p>	<p>Brad Pick Grifols Corporate Communications Brad.pick@grifols.com</p>
---	---

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with close to 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2020, Grifols' economic impact in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced jobs.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com



About ImmunoTek Bio Centers LLC

ImmunoTek Bio Centers LLC is the largest independent plasma collection company in the United States. The company is a global leader in developing a reliable plasma supply chain for biopharmaceutical companies specializing in plasma therapeutics and vaccines. Founded in 2013, ImmunoTek (including its predecessor) has built and operated more than 150 FDA-licensed and EU-certified plasma collection centers. ImmunoTek is rapidly expanding and plans to deliver an additional 60 plasma collection centers through 2023.

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.